Abstract

A series of potential topoisomerase II-mediated anticancer 9-anilinoacridine derivatives, which are designed to avoid bio-oxidation and possessed long duration of drug action, is reviewed. Among these agents, 3-(9-acridinylamino)-5- hydroxymethylaniline (AHMA) derivatives and their alkylcarbamates have been investigated and developed for potential clinical application.

Keywords: topoisomerase II, anticancer agents, bio-oxidation, potential clinical application, antitumor acridines, human leukemic ccrfcem cells, computer modelling, sar studies, supercoiled dna